Exabis Library
Welcome to the e-CCO Library!
P690: Rates of IBD in New Zealand Māori population at Lakes District Health Board: low but increasing
 2022
 ECCO'22
 Friday, 11 February 2022, 3:56 PM
P691 Corticosteroids usage in patients with inflammatory bowel disease: Results of a multi-national audit in Asia 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P691: Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P691: Disparate care: rates of treat to target among patients with inflammatory bowel disease
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P691: Influence of ethnicity on the phenotype and clinical outcomes in Inflammatory Bowel Disease; comparison of a South American with a North American population.
 2022
 ECCO'22
 Friday, 11 February 2022, 3:56 PM
P691: Trends in diagnostic prevalence and treatment patterns of adult ulcerative colitis patients in the USA, 2007–2017 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P691: UV exposure and skin type are more important than thiopurine exposure for non-melanoma skin cancer risk in IBD
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P692 Exploring relationships between microbiome, faecal calprotectin and healthy eating index in patients with ulcerative colitis: Interim analyses of a randomised controlled trial 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P692: Clinical, therapeutic and evolutionary profile of fistulizing ano-perineal lesions in Crohn's disease
 2022
 ECCO'22
 Friday, 11 February 2022, 3:56 PM
P692: Efficacy and safety of early biologic treatment of Crohn’s disease in adult and paediatric patients: A systematic review
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P692: Inflammatory bowel diseases in Faroese-born Danish residents and their offspring. Further evidence of the dominant role of environmental factors in IBD development
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P692: Positive histological margins is a risk factor of recurrence after ileocaecal resection in Crohn’s disease 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P693 Development and evaluation of i-TRACKER infliximab and i-TRACKER anti-Infliximab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with infliximab 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P693: Italian real-life study evaluating the long-term effectiveness of vedolizumab for the treatment of Inflammatory Bowel Disease- An IG-IBD study
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P693: Patients with inflammatory bowel disease who are on immunosuppressive therapy perform regular gynecologic screening for uterine cervical cancer?
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P693: Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P693: Vedolizumab treatment for pouch inflammation 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P693: Willingness and hesitancy to the telemedicine in patients with inflammatory bowel disease during COVID-19 outbreak. Preliminary results of a survey in an Italian IBD Center
 2022
 ECCO'22
 Friday, 11 February 2022, 3:56 PM
P694 Validation of two commercial assays for therapeutic drug monitoring of adalimumab biosimilars 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P694: COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy.
 2022
 ECCO'22
 Friday, 11 February 2022, 3:56 PM